Drugs / APH-1501
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03813095 | Oct 2023 → Sep 2025 | opiate dependence, substance withdrawal syndrome | Aphios | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APH-1501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03813095 ↗ |
| Known as | Cannabidiol | “This is a Phase 2a Exploratory Pilot study assessing the efficacy, immunogenicity and pharmacology of APH-1501, Cannabidiol (CBD), a unique, bioactive component of marijuana,...” NCT03813095 ↗ |
| Known as | CBD | “This is a Phase 2a Exploratory Pilot study assessing the efficacy, immunogenicity and pharmacology of APH-1501, Cannabidiol (CBD), a unique, bioactive component of marijuana,...” NCT03813095 ↗ |
| Route | Oral | “intended for oral administration” NCT03813095 ↗ |